Annexon Inc (NAS:ANNX)
$ 5.39 0.05 (0.94%) Market Cap: 574.54 Mil Enterprise Value: 264.03 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 40/100

Annexon Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 06:30PM GMT
Release Date Price: $4.41 (-6.77%)
Phil Nadeau
TD Cowen - Analyst

Welcome once again to TD Cowen's 43rd annual healthcare conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to do a fireside chat with Annexon. We have Doug Love, President and CEO of Annexon, with us this afternoon.

Questions & Answers

Phil Nadeau
TD Cowen - Analyst

Doug, in January Annexon announced plans to prioritize four programs. Could you briefly outline Annexon's overall strategy, the four programs that were prioritized and the rationale?

Doug Love
Annexon Inc. - President & CEO

Yeah, absolutely. So, as you all know, we're focused on the classical pathway in C1q, the initiator of the pathway. One of the things that's been quite unique in the complement space is its druggability. It's been really well validated clinically and now commercially in a host of different diseases in autoimmune and neurodegeneration.

Based on work we've done in an early set of our pipeline programs, we decided to focus on four key

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot